Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease

EJNMMI Research

Table 1 Representation of the cases for diagnosis and PET/CT intensity values

Case	Final diagnosis	Location	Biopsy	Pain	RAPD	Proptosis (Hertel in mm)	BCVA	PET SUVmax lesion	PET SUVmax bone marrow	PET SUV max LN level 2
1	IOI	Apex with posterior extension	–	Moderate	No	Yes (24–20)	0.6	1.04 (moderate)	2.07	11.36
2	IOI	Myositis	+	Severe	No	Yes^a	1.0	0.68 (low)	2.01	7.97
3	IOI	Lacrimal gland	+	Moderate	No	No	1.2	3.88 (high)	5.32	11.32
4	TED	Pan-myositis	–	None	No	Yes (23–23)	1.0	0.33 (low)	2.91	5.45
5	IgG4+	Myositis	+	Mild	No	Yes (16–24)	1.2	1.58 (moderate)	4.43	8.90
6	IOI	Diffuse mass	+	Moderate	No	Yes^a	0.9	3.11 (high)	3.73	15.87
7	IOI	Diffuse mass	+	Moderate	No	Yes^a	1.0	2.12 (high)	3.27	14.45
8	Meningioma	Apex	–	None	Yes	No	0.6	0.79 (low)	2.49	5.81
9	IOI	Diffuse mass	+	Severe	Yes	No	0.5	3.82 (high)	3.64	12.12
10	TED	Pan-myositis	–	Mild	No	Yes (29–29)	0.7	3.47 (high)	4.07	12.10
11	IOI	Myositis	+	Severe	No	No	0.9	4.24 (high)	3.52	13.71
12	IOI	Myositis	+	Severe	No	No	1.0	0.68 (low)	4.83	19.15

IOI = idiopathic orbital inflammation; TED = thyroid eye disease; RAPD = relative afferent pupillary defect; BCVA = best-corrected visual acuity
^aClinical and radiological proptosis, not quantified with Hertel